Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Cytokinetics Inc (NASDAQ: CYTK) closed at $51.5 in the last session, down -1.13% from day before closing price of $52.09. In other words, the price has decreased by -$1.13 from its previous closing price. On the day, 1.87 million shares were traded. CYTK stock price reached its highest trading level at $52.13 during the session, while it also had its lowest trading level at $50.41.
Ratios:
We take a closer look at CYTK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.76 and its Current Ratio is at 6.76.
On April 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $55. On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.Citigroup initiated its Buy rating on February 07, 2025, with a $86 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 02 ’25 when Kaye Edward M. MD sold 6,756 shares for $50.00 per share. The transaction valued at 337,800 led to the insider holds 23,230 shares of the business.
ROBERT HARRINGTON bought 4,300 shares of CYTK for $151,919 on Sep 02 ’25. On Sep 02 ’25, another insider, Harrington Robert Arthur, who serves as the Director of the company, sold 2,150 shares for $48.67 each. As a result, the insider received 104,640 and left with 20,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6162335744 and an Enterprise Value of 6295966720. For the stock, the TTM Price-to-Sale (P/S) ratio is 71.87. Its current Enterprise Value per Revenue stands at 73.433 whereas that against EBITDA is -11.711.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.56, which has changed by -0.042216837 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $59.39, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 34.38%, while the 200-Day Moving Average is calculated to be 25.12%.
Shares Statistics:
According to the various share statistics, CYTK traded on average about 1.83M shares per day over the past 3-months and 3843630 shares per day over the past 10 days. A total of 119.60M shares are outstanding, with a floating share count of 117.02M. Insiders hold about 2.21% of the company’s shares, while institutions hold 114.18% stake in the company. Shares short for CYTK as of 1755216000 were 15325098 with a Short Ratio of 8.39, compared to 1752537600 on 15929741. Therefore, it implies a Short% of Shares Outstanding of 15325098 and a Short% of Float of 16.700001.
Earnings Estimates
The current rating of Cytokinetics Inc (CYTK) reflects the combined expertise of 16.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.57, with high estimates of -$1.21 and low estimates of -$2.06.
Analysts are recommending an EPS of between -$4.95 and -$6.3 for the fiscal current year, implying an average EPS of -$5.62. EPS for the following year is -$5.75, with 14.0 analysts recommending between -$4.09 and -$7.21.
Revenue Estimates
A total of 19 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $153.83M, while the lowest revenue estimate was $68.3M, resulting in an average revenue estimate of $83.58M. In the same quarter a year ago, actual revenue was $18.47MBased on 17 analysts’ estimates, the company’s revenue will be $148.66M in the next fiscal year. The high estimate is $402M and the low estimate is $33.9M.
